As of June 30, 2026, Acusensus Ltd carries a market capitalization of 210.05M, placing it among publicly traded companies globally. Its enterprise value stands at 192.58M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 210.05M |
| Enterprise Value | 192.58M |
Acusensus Ltd's next confirmed earnings release is scheduled for February 23, 2027.
| Earnings Date | 2/23/2027 |
As of June 30, 2026, Acusensus Ltd has 169.40M shares outstanding.
| Shares Outstanding | 169.40M |
These figures are as of June 30, 2026. The price-to-sales ratio is 2.23, and the price-to-book ratio stands at 3.30.
| PS Ratio | 2.23 |
| PB Ratio | 3.30 |
| P/TBV Ratio | 3.47 |
These figures are as of June 30, 2026. The EV/Sales ratio of 2.23 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 192.58M versus a market cap of 210.05M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 2.23 |
As of June 30, 2026, Acusensus Ltd maintains a current ratio of 2.26, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.94, indicating elevated leverage, while an interest coverage ratio of -93.85 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.26 |
| Quick Ratio | 2.01 |
| Debt / Equity | 11.94 |
| Debt / EBITDA | -0.59 |
| Interest Coverage | -93.85 |
Over the twelve months ended June 30, 2026, Acusensus Ltd posted a negative return on equity (ROE) of -44.02, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -28.73, reflecting losses generated across the asset base. The company generates approximately 234,787.47 in revenue per employee across its workforce of 367.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 22.83 indicates how many times Acusensus Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | -44.02 |
| Return on Assets (ROA) | -28.73 |
| Revenue Per Employee | 234,787.47 |
| Employee Count | 367.00 |
| Inventory Turnover | 22.83 |
Over the twelve months ended June 30, 2026, Acusensus Ltd recorded 182,000.00 in income tax expense. The company reported a pretax loss of -24.11M and -24.29M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 182,000.00 |
As of the close on November 17, 2026, Acusensus Ltd's stock has declined approximately 39.06% over the past 52 weeks. The 50-day moving average sits at 1.10, while the 200-day moving average is 1.31.
| 52-Week Price Change | -39.06% |
| 50-Day Moving Average | 1.10 |
| 200-Day Moving Average | 1.31 |
Over the twelve months ended June 30, 2026, Acusensus Ltd generated 86.17M in revenue and converted that into -24.29M in net income, yielding earnings per share of -0.16. EBITDA reached -12.95M, while operating income came in at -23.91M.
| Revenue | 86.17M |
| Gross Profit | 36.16M |
| Operating Income | -23.91M |
| Pretax Income | -24.11M |
| Net Income | -24.29M |
| EBITDA | -12.95M |
| EBIT | -24.61M |
| Earnings Per Share (EPS) | -0.16 |
As of June 30, 2026, Acusensus Ltd holds 25.06M in cash and equivalents against 7.59M in total debt, resulting in a net debt position of -24.98M. Total book value stands at 63.58M, with working capital of 27.25M providing operational flexibility.
| Cash & Cash Equivalents | 25.06M |
| Total Debt | 7.59M |
| Net Debt | -24.98M |
| Equity (Book Value) | 63.58M |
| Book Value Per Share | 0.38 |
| Working Capital | 27.25M |
These figures cover the twelve months ended June 30, 2026.
| Capital Expenditures | -18.27M |
Over the twelve months ended June 30, 2026, Acusensus Ltd posted a gross margin of 41.96, reflecting its pricing power and cost economics. The operating margin of -27.75 and net profit margin of -28.19 provide insight into operational efficiency.
| Gross Margin | 41.96 |
| Operating Margin | -27.75 |
| Pretax Margin | -27.98 |
| Profit Margin | -28.19 |
| EBITDA Margin | -15.03 |
These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -12.54, meaning Acusensus Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -12.54 |
Acusensus Ltd's most recent stock split took place on July 28, 2023 with a 1:5 split ratio.
| Last Split Date | 7/28/2023 |
| Split Ratio | 1:5 |
As of June 30, 2026, Acusensus Ltd has an Altman Z-Score of 3.89, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.89 |
Already premium?